Bayer Investor Relations

A bird's eye view of a building with a logo on it.
News from Bayer
April 16, 2024
Not intended for UK Media
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease
March 19, 2024
Not intended for UK Media
Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer’s elinzanetant
March 05, 2024
Financial News Conference:
Bayer aims to enhance performance and regain strategic flexibility by 2026 – adjusted guidance for 2023 achieved